The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
- PMID: 19855401
- PMCID: PMC4144869
- DOI: 10.1038/nrmicro2236
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Abstract
Immunological tests provide evidence of latent tuberculosis in one third of the global population, which corresponds to more than two billion individuals. Latent tuberculosis is defined by the absence of clinical symptoms but carries a risk of subsequent progression to clinical disease, particularly in the context of co-infection with HIV. In this Review we discuss the biology of latent tuberculosis as part of a broad range of responses that occur following infection with Mycobacterium tuberculosis, which result in the formation of physiologically distinct granulomatous lesions that provide microenvironments with differential ability to support or suppress the persistence of viable bacteria. We then show how this model can be used to develop a rational programme to discover effective drugs for the eradication of M. tuberculosis infection.
Figures
Comment in
-
Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes.Nat Rev Microbiol. 2010 Mar;8(3):242; author reply 242. doi: 10.1038/nrmicro2236-c1. Epub 2010 Jan 19. Nat Rev Microbiol. 2010. PMID: 20084059 No abstract available.
Similar articles
-
National position statement for the management of latent tuberculosis infection.Commun Dis Intell Q Rep. 2017 Sep 1;41(3):E204-E208. Commun Dis Intell Q Rep. 2017. PMID: 29720068
-
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques.Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14188-93. doi: 10.1073/pnas.1121497109. Epub 2012 Jul 23. Proc Natl Acad Sci U S A. 2012. PMID: 22826237 Free PMC article.
-
Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.Molecules. 2020 Mar 11;25(6):1259. doi: 10.3390/molecules25061259. Molecules. 2020. PMID: 32168746 Free PMC article. Review.
-
Mycobacterium tuberculosis strain 18b, a useful non-virulent streptomycin dependent mutant to study latent tuberculosis as well as for in vivo and in vitro testing of anti-tuberculosis drugs.Tuberculosis (Edinb). 2016 Jul;99:54-55. doi: 10.1016/j.tube.2016.04.006. Epub 2016 Apr 23. Tuberculosis (Edinb). 2016. PMID: 27450005 No abstract available.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
-
Expression of specific HLA class II alleles is associated with an increased risk for active tuberculosis and a distinct gene expression profile.HLA. 2023 Feb;101(2):124-137. doi: 10.1111/tan.14880. Epub 2022 Nov 20. HLA. 2023. PMID: 36373948 Free PMC article.
-
The granuloma in tuberculosis: dynamics of a host-pathogen collusion.Front Immunol. 2013 Jan 7;3:411. doi: 10.3389/fimmu.2012.00411. eCollection 2012. Front Immunol. 2013. PMID: 23308075 Free PMC article.
-
Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.Bioorg Med Chem. 2013 Sep 1;21(17):5605-17. doi: 10.1016/j.bmc.2013.05.024. Epub 2013 May 24. Bioorg Med Chem. 2013. PMID: 23845282 Free PMC article.
-
Profiling the Proteome of Mycobacterium tuberculosis during Dormancy and Reactivation.Mol Cell Proteomics. 2015 Aug;14(8):2160-76. doi: 10.1074/mcp.M115.051151. Epub 2015 May 29. Mol Cell Proteomics. 2015. PMID: 26025969 Free PMC article.
-
The Importance of First Impressions: Early Events in Mycobacterium tuberculosis Infection Influence Outcome.mBio. 2016 Apr 5;7(2):e00342-16. doi: 10.1128/mBio.00342-16. mBio. 2016. PMID: 27048801 Free PMC article. Review.
References
-
- Comstock GW, Baum C, Snider DE., Jr Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119:827–30. - PubMed
-
- Stead WW. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med. 1995;122:906–12. - PubMed
-
- Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends in Microbiology. 2009 Epub ahead of print. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources